IL6 and colorectal carcinoma: mTORC1 plays various roles in different types of CRC.[44] For example, CRC with APC mutations shows increased mTORC1 activity, which is associated with enhanced tumor growth.[45] On the other hand, in inflammation‐induced CRC, inactivation of mTORC1 leads to increased chromosomal instability and impairs regeneration of intestinal crypts, triggers interleukin‐6‐associated reparative inflammation, and induces crypt hyper‐proliferation, wound healing, and CRC.[37] It has proved that blocking IL‐6 signaling can reduce inflammation‐induced colorectal cancer.